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Received June 13, 2012; accepted October 31, 2012AbstractBackground: Mutations in the TREX1 and NOTCH3 genes cause retinal vasculopathy with cerebral leukodystrophy (RVCL) and cerebral
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), respectively. Both are hereditary small vessel
diseases of the brain (HSVDB).
Methods: We performed mutational analyses of TREX1 in genomic DNA from 39 unrelated patients who were NOTCH3-negative in genetic
testing, selected out of 72 unrelated consecutive patients with HSVDB.
Results: Only one patient had a TREX1 sequence variation, a heterozygous TREX1 c.294dupA, putatively resulting in a truncated protein,
p.C99MfsX3. The medical history of the patient’s family was scrutinized, which revealed that heterozygous TREX1 p.C99MfsX3 was not
segregating with the HSVDB. Re-examination of the NOTCH3 sequence data of the proband led to the identification of a homozygous NOTCH3
c.1630C>T (p.R544C) mutation, which segregated with the HSVDB in the family. The proband had a slightly more severe phenotype in
comparison with her heterozygous p.R544C sister.
Conclusion: TREX1 mutation is not a common cause of HSVDB. TREX1 p.C99MfsX3 is not a dominant mutation. Homozygosity of the
NOTCH3 p.R544C has a modestly deleterious effect on the CADASIL phenotype. The NOTCH3 mutation may cause CADASIL through a gain-
of-toxic function effect, which can be modified by other genetic or environmental factors and results in the phenotypic variation of CADASIL.
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http://dx.doi.org/10.1016/j.jcma.2013.03.002sharing common characteristics of multiple lacunar infarctions
and diffuse leukoencephalopathy. Cerebral autosomal domi-
nant arteriopathy with subcortical infarcts and leukoence-
phalopathy (CADASIL) and retinal vasculopathy with cerebral
leukodystrophy (RVCL) are two different HSVDB with
clearly identified genetic causes.1,2 CADASIL is the most
common monogenic HSVDB, caused by NOTCH3 mutations.
It is an adult-onset, dominantly inherited disease with recur-
rent ischemic strokes, dementia, and less frequently, migrainehinese Medical Association. All rights reserved.
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receptor, NOTCH3, which is expressed on vascular smooth
muscle cells and plays an important role in arterial develop-
ment.4 It is a single-pass transmembrane protein with a large
extracellular domain containing 34 tandem epidermal growth
factor-like (EGF-like) repeats. There are six cysteine residues
within each EGF-like repeat and almost all mutations identi-
fied in CADASIL to date result in either a gain or loss of one
cysteine residue within a given EGF-like repeat domain of the
NOTCH3 protein.5 As the NOTCH3 mutations leave one
cysteine residue unpaired, which provides one free sulfhydryl
group, the mutant NOTCH3 molecules may interact with
adjacent mutant NOTCH3 or other proteins by aberrant di-
sulfide bond formation. The structurally altered proteins may
accumulate nearby and become toxic to the vascular smooth
muscle cells.4
RVCL is a rare autosomal dominant disease. It features a
combination of various symptoms such as progressive visual
loss, ischemic stroke, dementia, migraine, and Raynaud’s
phenomenon attributable to retinal, cerebral, and systemic
microangiopathy.2 RVCL encompasses three previously
described neurovascular syndromes, including cerebroretinal
vasculopathy (CRV),6 hereditary endotheliopathy, retinopathy,
and nephropathy (HERNS)7,8 and hereditary vascular reti-
nopathy (HVR),9 and has been found to be caused by C-ter-
minal truncations in human 30-50 DNA exonuclease (TREX1).2
TREX1 serves a DNA proofreading function and is also
involved in the regulation of immunity and granzyme A-
mediated apoptosis.10,11 In addition to RVCL, different
TREX1 mutations have been associated with Aicardi-Gou-
tie`res syndrome (AGS),12 familial chilblain lupus (FCL),13
and systemic lupus erythematosus (SLE).2 AGS is an auto-
somal recessive infantile encephalopathy with brain atrophy,
leukodystrophy, basal ganglia calcification, chronic cerebro-
spinal fluid (CSF) lymphocytosis, and elevated a-interferon
levels in CSF. FCL is a rare cutaneous form of SLE, pre-
senting with painful bluish-red inflammatory acral skin lesions
in early childhood. FCL and most SLE are autosomal domi-
nant diseases.
Vascular retinopathy is the most prominent symptom of
RVCL, and most patients with RVCL reported to date have
been diagnosed with retinopathy prior to genetic testing.6e9
The genetic etiologies of many patients with isolated
HSVDB remain elusive. It is still unknown whether TREX1
mutations may still be associated with HSVDB in the absence
of retinopathy. Therefore, to further understand the genetic
basis of HSVDB, we were determined to investigate TREX1
mutations in HSVDB patients without retinopathy.
We performed mutational analyses of TREX1 in genomic
DNA from 39 unrelated patients without gross NOTCH3
mutations in genetic testing; they were selected out of 72
unrelated consecutive patients with HSVDB. Only one pa-
tient had a TREX1 sequence variation, a heterozygous
TREX1 c.294dupA, putatively resulting in a truncated pro-
tein, p.C99MfsX3. Study of the patient’s family revealed
that heterozygous TREX1 p.C99MfsX3 was not segregating
with the HSVDB. Re-scrutiny of the NOTCH3 sequencedata of the proband led to the identification of a homozy-
gous NOTCH3 c.1630C>T (p.R544C) mutation, which
segregated well with the HSVDB in the family. Herein, we
describe the clinical, genetic, and magnetic resonance im-
aging (MRI) features of this HSVDB family harboring the
homozygous NOTCH3 p.R544C mutation and the hetero-
zygous TREX1 p.C99MfsX variant. This study also expands
the general base of knowledge about the role of TREX1
mutations in HSVDB.
2. Methods
The protocols for this study were approved by the insti-
tutional review board of Taipei Veterans General Hospital.
Written informed consent was obtained from all
participants.2.1. PatientsThe study population consisted of 39 patients out of 72
unrelated consecutive patients with HSVDB who were
recruited from the Neurology Service, Taipei Veterans General
Hospital. These patients had previously tested negative for
NOTCH3 mutations. The mean age (SD) of the study pop-
ulation was 53.8  13.4 years (range 31e78 years), and 28 of
them (71.8%) were male. Twenty patients had hypertension
(51.3%), and 11 had diabetes mellitus (DM; 28.2%). The
initial clinical manifestations of our patients included ischemic
stroke in 24 patients (61.5%), dementia in seven (17.9%),
hemorrhagic stroke in four (10.3%), progressive gait distur-
bance in three (7.7%), and bipolar disease in one (2.6%). No
patient had any visual complaints. All patients were of Han
Chinese descent and had at least one other affected family
member with a history of ischemic stroke or vascular de-
mentia. The presence of cerebral small vessel disease was
defined as leukoaraiosis in addition to multiple lacunar infarcts
on the brain MRI.2.2. Mutational analysisGenomic DNA was extracted from peripheral blood using
standard protocols. Mutation analyses of TREX1 and exons 2
to 24 of NOTCH3 were performed by polymerase chain re-
action (PCR) amplification using intronic primers and direct
nucleotide sequencing. Both sense- and antisense-strands of
all amplicons were sequenced using the Big Dye 3.1 dideoxy
terminator methods (Applied Biosystems, Foster City, CA,
USA) and ABI Prism 3700 Genetic Analyzer (Applied Bio-
systems). The amplicon sequences were compared with the
published human gene sequences (TREX1, RefSeq
NM_033629.2; NOTCH3, RefSeq NM_000435.2) in the Na-
tional Center for Biotechnology Information (NCBI) database
(http://www.ncbi.nlm.nih.gov). After the identification of the
sequence variations, subcloning and subsequent sequence an-
alyses of the amplicons were further performed to confirm the
sequence changes.
321B.-W. Soong et al. / Journal of the Chinese Medical Association 76 (2013) 319e3243. Results3.1. Mutational analysisOut of the 39 patients, only one (III:4) (Fig. 1) was found to
carry a heterozygous TREX1 c.294dupA mutation (Fig. 2A),
which was confirmed by the subcloning of the PCR products
and repeated sequencings and was not found in 300 healthy
controls. This single nucleotide insertion caused a frameshift
that resulted in expression of a putatively truncated TREX1
protein, p.C99MfsX3. TREX1 c.294dupA was not a typical
causative mutation for RVCL, which was most frequently re-
ported as a C-terminal truncation of TREX1. To explore the
pathogenic role of TREX1 c.294dupA in this family with
HSVDB, we sequenced two other affected and two healthy
members of the family and realized that TREX1 c.294dupA
did not segregate with the HSVDB in this family (Fig. 1).
To look into the genetic etiology of disease in this family,
we re-examined the original sequence reads of NOTCH3 of
III:4 and unexpectedly, identified a homozygous NOTCH3
c.1630C>T (p.R544C) mutation (Fig. 2B), which was over-
looked in the first sequence reading. The homozygous
NOTCH3 c.1630C>T mutation was confirmed by repeated
PCR amplification and sequencing using two different sets of
primers to avoid false homozygosity from asymmetric PCR
amplification. The other aforementioned family members were
also re-sequenced. NOTCH3 p.R544C segregated well with
the HSVDB in the family, suggesting that NOTCH3 p.R544C,
rather than TREX1 p.C99MfsX3, caused HSVDB in this
particular pedigree. Re-examination of the original sequence
of NOTCH3 of the other 38 patients confirmed the absence of
mutation in either NOTCH3 or TREX1.Fig. 1. The pedigree with hereditary small vessel disease of the brain (HSVDB) simu
with NOTCH3 p.R544C, rather than TREX1 p.C99MfsX3. Affected individuals are
deceased individuals. Below the symbol is the age at examination or death.3.2. Clinical information of the familyThe proband III:4, at the age of 63 years, presented with a
3-month history of left hemiparesis and memory impairment.
She denied any previous history of stroke, migraine, or psy-
chiatric symptoms, but her father and three other siblings all
previously had strokes. She did not have other vascular risk
factors, such as hypertension, DM, cigarette smoking, or
hyperlipidemia. Physical examinations revealed a mild
weakness in the left lower limb (4þ/5 according to the Med-
ical Research Council scale) and slightly more brisk deep
tendon reflexes in the left knee and ankle. Her score on the
Mini-Mental State Examination (MMSE) was 24 out of 30.
Brain MRI revealed diffuse white matter abnormalities with
anterior temporal lobe involvement and a few lacunar infarcts
in the corona radiata and the right putamen (Fig. 3A). Muta-
tional analyses identified a heterozygous TREX1 p.C99MfsX3
(c.294dupA) mutation (Fig. 2A) and a homozygous NOTCH3
p.R544C (c.1630C>T) mutation (Fig. 2B). She did not have
any clinical manifestation suggesting SLE or Sjo¨gren’s syn-
drome (SS), and her serum antinuclear antibody testing was
negative. Additionally, fluorescein angiography revealed no
retinal vasculopathy.
The proband’s eldest sister (III:1) had a nasopharyngeal
carcinoma with radiotherapy at the age of 65 years, a temporal
lobe epilepsy originating from the left medial temporal region
at the age of 67 years, and a mild stroke resulting in dysarthria
at the age of 70 years. She did not have other major vascular
risk factors. Brain MRI at the age of 67 years revealed mild
but diffuse white matter abnormalities with anterior temporal
lobe involvement and a lacunar infarct in the left corona
radiata (Fig. 3B). Her score on the MMSE at the age ofltaneously harboring TREX1 and NOTCH3 mutations. The HSVDB segregates
shown as filled symbols and the arrow points to the proband. A slash indicates
Fig. 2. (A) The electropherograms demonstrating a heterozygous c.294dupA
mutation in the TREX1 gene and a limited reading frame depicting the cor-
responding amino acid substitutions (p.C99MfsX3). (B) The electrophero-
grams demonstrating a homozygous and a heterozygous c.1630C>T mutation
in the NOTCH3 gene, with a limited reading frame depicting the corre-
sponding amino acid substitutions (p.R544C).
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NOTCH3 p.R544C (c.1630C>T) mutation and wild-type
TREX1 genes.
The proband’s elder sister (III:3) with DM and hypercho-
lesterolemia had her first ischemic stroke at 58 years of age
with residual gait difficulty, which was followed by repeated
ischemic events resulting in dysarthria and dysphagia at the
age of 62 years, and severe dementia at the age of 64 years. A
brain CT at age 66 years featured a marked diffuse white
matter abnormality with multiple lacunar infarcts in the corona
radiata and basal ganglia. Mutational analysis revealed a
NOTCH3 homozygous p.R544C (c.1630C>T) mutation and
wild-type TREX1 genes.
The proband’s younger sister (III:5), at the age of 60 years,
and brother (III:6), at the age of 55 years, both had normal
brain MRI and appeared normal on physical examinations.
Mutational analysis revealed that III:5 had wild-type NOTCH3
and TREX1 genes, while III:6 had wild-type NOTCH3 genes
but a heterozygous TREX1 mutation, p.C99MfsX3. III:6 had
no clinical features suggesting either SLE or SS. The pro-
band’s elder brother (III:2) allegedly had repeated ischemic
strokes. The clinical information about the proband’s father
(II:3) and mother (II:4) was not available.4. Discussion
This is the first TREX1 study in a cohort of HSVDB that did
not involve significant patient visual complaints. We demon-
strated that TREX1 mutation was not present in a consecutive
series of 72 patients with HSVDB and, unexpectedly, identi-
fied a patient harboring both a heterozygous TREX1
p.C99MfsX3 and a homozygous NOTCH3 p.R544C. Given the
clinical manifestations, neuroimage features, and genotype
information of the family members, NOTCH3 p.R544C, rather
than TREX1 p.C99MfsX3, was likely to be the cause of
HSVDB in this family. These findings may have five
implications.
First, TREX1 mutation is not a common cause of HSVDB.
Although C-terminal truncating mutation in TREX1 has been
identified as the leading cause of RVCL,2 only a limited
number of RVCL families have been reported, indicating that
RVCL is not a common disease. Therefore, in clinical practice,
testing for TREX1 mutations is only warranted in patients with
both HSVDB and documented retinopathy or a family history
of TREX1 mutation. It is unclear if our findings are also
applicable to families with other ethnic backgrounds. Inves-
tigating TREX1 mutation in HSVDB patients from different
ethnic populations may provide more information about the
role of TREX1 in HSVDB.
Second, our data suggests that TREX1 p.C99MfsX3 is
likely nonpathogenic or a recessive mutation based on several
observations: (1) the younger brother (III:6) who carried a
heterozygous TREX1 p.C99MfsX3 has thus far remained
clinically disease-free (confirmed through neuroimaging
studies), and the proband (III:4) and her younger brother
(III:6) had neither AGS, FCL, SLE, nor SS; (2) the proband
(III:4) harboring this mutation and a homozygous NOTCH3
mutation had a later disease onset and less disease severity
than her elder sister (III:3) who only had the homozygous
NOTCH3 mutation. The TREX1 protein is composed of three
conserved motifs, including an active catalytic domain and a
highly hydrophobic transmembrane C-terminal domain.2,14
All of the patients with RVCL reported so far have C-termi-
nal frameshift mutations in the TREX1 gene, leading to the
production of proteins with truncated transmembrane domain
and altered intracellular localization but preserved enzymatic
function.2 The p.C99MfsX3 TREX1 mutant protein is ex-
pected to lose two-thirds of its amino acid residues, including
exonuclease regions, and is likely a recessive nonfunctional
mutation. The single-copy wild-type allele may produce suf-
ficient TREX1 protein to maintain the physiological function.
This may well explain why heterozygous carriers of TREX1
p.C99MfsX3 remain clinically “invisible”.
Third, homozygosity of the NOTCH3 p.R544C mutation
only mildly aggravated the CADASIL phenotype. NOTCH3
R544C mutation is very common and accounts for approxi-
mately one half of CADASIL among the Chinese population
in Taiwan.15 This pedigree, with two patients (III3 and III4)
harboring homozygous p.R544C, offers a rare and valuable
opportunity to assess the effects of homozygous NOTCH3
mutation on the phenotype of CADASIL. Compared with the
Fig. 3. Fluid attenuated inversion recovery (FLAIR) images depicting multiple lacunar infarcts and diffuse leukoencephalopathy with involvement of corona
radiata, external capsules, and anterior temporal poles in III-4 with a homozygous NOTCH3 p.R544C mutation (A), her sister (III-1) with a heterozygous NOTCH3
mutation (B), and another unrelated 61-year-old female with a heterozygous NOTCH3 p.R544C mutation (C).
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a slightly earlier age of onset and mildly increased clinical
severity, suggesting that under a similar genetic background,
homozygosity of the NOTCH3 mutation might have a dosage-
dependent, albeit small, effect on the phenotype of CADASIL.
Fourth, the phenotype of CADASIL may be modified by
other genetic or environment factors in addition to NOTCH3
mutation. The mean age of onset of CADASIL in our popu-
lation was 47.6 years.15 However, the proband and her sister
(III-3) harboring homozygous R544C mutation had ages of
onset (63 and 58 years) later than the average, suggesting the
existence of other modifying genetic and/or environmental
factors that alleviate the phenotype of CADASIL. Compared
with the proband, her homozygous sister (III-3) with DM and
hyperlipidemia had a more severe phenotype, raising the
possibility that other vascular risk factors may worsen the
severity of CADASIL.Lastly, theNOTCH3mutations causingCADASILmaywork
through a gain-of-toxic function mechanism. NOTCH3 is pre-
dominantly expressed in small arterial smooth-muscle cells and
is vital for their differentiation and maturation.5 Thus, if
CADASIL-associated NOTCH3 mutations worked through a
haploinsufficiency or dominant-negative effect, homozygous
mutations would have been devastating and lead to a more se-
vere or lethal phenotype. In the literature, two patients with
disparate homozygous NOTCH3 mutations have been sepa-
rately reported before. One patient with a homozygous p.R133C
had a severe phenotype of CADASIL,16 and the other onewith a
homozygous p.R578C had a very mild phenotype, which was
not significantly different from that of the heterozygous sib-
ling.17 Two sisters with homozygous p.R544C in our study had a
typical CADASIL with later age of onset. The highly variable
clinical features of the patients with homozygous NOTCH3
mutations suggest that the phenotypic presentations of
324 B.-W. Soong et al. / Journal of the Chinese Medical Association 76 (2013) 319e324CADASIL are not solely dictated by the NOTCH3 mutations,
but may also be modified by other factors.
In the electropherogram (Fig. 2B), heterozygous mutations,
which would appear as double peaks in two different colors at
the same nucleotide location, are very conspicuous and
therefore hard to miss. However, homozygous mutations,
which would appear as a single overlapping peak in one single
color, are easily overlooked by visual inspection. As CADA-
SIL is an autosomal dominant disease, homozygous NOTCH3
mutations in CADASIL rarely occur. Therefore, in our earlier
experience, we focused on heterozygous variants on the
electropherogram of NOTCH3 sequencing and, therefore,
missed one single NOTCH3 R544C homozygous mutation.
After realizing this oversight, we now routinely double-check
all our electropherograms involved with NOTCH3 sequencing
in all patients to make sure this will never happen again.
In conclusion, this study demonstrates that TREX1 mutation
is not a common cause of HSVDB. TREX1 p.C99MfsX3 is not
a dominant mutation. A single copy of wild-type TREX1 may
be functionally sufficient. Homozygous NOTCH3 p.R544C
mutation had slightly enhanced deleterious effect on CADA-
SIL phenotype. A gain-of-toxic function effect of the
NOTCH3 mutation may be responsible for the pathogenesis of
CADASIL, which could be modified by other genetic or
environmental factors and results in the phenotypic variation
of CADASIL.
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